IL-17 as a future therapeutic target for rheumatoid arthritis

Nature Reviews Rheumatology

Volumn 5, Issue 10, 2009, Pages 549-553

  van den Berg, Wim B ^a   Miossec, Pierre ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 6; PLACEBO; PROTEIN ANTIBODY; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

BONE DESTRUCTION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG TARGETING; HUMAN; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; TH17 CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-17; JOINTS; SYNOVIAL MEMBRANE; TH1 CELLS;

EID: 70349968220     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.179     Document Type: Review

References (68)

1. Yao, Z. et al. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155, 5483-5486 (1995).
2. Rouvier, E., Luciani, M. F., Mattei, M. G., Denizot, F. & Golstein, P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpes virus saimiri gene. J. Immunol. 150, 5445-5456 (1993).
3. Miossec, P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum. 56, 2111-2115 (2007).
4. Fossiez, F. et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183, 2593-2603 (1996).
5. Kolls, J. K. & Lindén, A. Interleukin-17 family members and inflammation. Immunity 21, 467-476 (2004).
6. Iwakura, Y., Nakae, S., Saijo, S. & Ishigame, H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol. Rev. 226, 57-79 (2008).
7. Kotake, S. et al. IL-17 in synovial fluids from patients with RA is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103, 1345-1352 (1999).
8. Koenders, M. I. et al. Induction of cartilage damage by overexpression of T cell IL-17A in experimental arthritis in mice deficient in IL-1. Arthritis Rheum. 52, 975-983 (2005).
9. Gaffen, S. L. An overview of IL-17 function and signaling. Cytokine 43, 402-407 (2008).
10. Toy, D. et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J. Immunol. 177, 36-39 (2006).
11. Maitra, A. et al. Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression. Proc. Natl Acad. Sci. USA 104, 7507-7511 (2007).
12. + CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J. Immunol. 180, 655-663 (2008).
13. H2 cells. J. Immunol. 162, 1246-1251 (1999).
14. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123-1132 (2005).
15. H17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24, 677-688 (2006).
16. H17 cells. Nature 453, 1051-1057 (2008).
17. + T helper cells. Cell 126, 1121-1133 (2006).
18. Aggarwal, S., Ghilardi, N., Xie, M. H., de Sauvage, F. J. & Gurney, A. L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910-1914 (2003).
19. H17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203, 2271-2279 (2006).
20. H17 cytokine IL-22 in collagen-induced arthritis in C57Bl/6 mice. Arthritis Rheum. 60, 390-395 (2009).
21. Lubberts, E. et al. IL-1 independent role of IL-17 in synovial inflammation and joint destruction during collagen induced arthritis. J. Immunol. 167, 1004-1013 (2001).
22. Miossec, P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum. 48, 594-601 (2003).
23. H17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673-2682 (2006).
24. Koenders, M. I., Joosten, L. A. & van den Berg, W. B. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relations to tumour necrosis factor and IL-1 in experimental arthritis. Ann. Rheum. Dis. 65 (suppl. 3), iii29-iii33 (2006).
25. Koenders, M. I. et al. Interleukin-17 acts independently of TNF-α under arthritic conditions. J. Immunol. 176, 6262-6269 (2006).
26. Nakae, S., Nambu, A., Sudo, K. & Iwakura, Y. Suppression of immune induction of collagen-induced arthritis in Il-17 deficient mice. J. Immunol. 171, 6173-6177 (2003).
27. 1 Fc fusion protein. Arthritis Rheum. 46, 802-805 (2002).
28. Lubberts, E. et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen induced arthritis reduces joint inflammation, cartilage destruction and bone erosion. Arthritis Rheum. 50, 650-659 (2004).
29. Koenders, M. I. et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am. J. Pathol. 167, 141-149 (2005).
30. Abdollahi-Roodsaz, S. et al. Shift from Toll-like receptor 2 (TLR2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production. Arthritis Rheum. 58, 3753-3764 (2008).
31. Ogura, H. et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29, 628-636 (2008).
32. Iwakura, Y. & Ishigame, H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116, 1218-1222 (2006).
33. H cells that cause autoimmune arthritis. J. Exp. Med. 204, 41-47 (2007).
34. Nakae, S. et al. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl Acad. Sci. USA 100, 5986-5990 (2003).
35. H17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum. 58, 3461-3470 (2008).
36. Abdollahi-Roodsaz, S. et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J. Clin. Invest. 118, 205-216 (2008).
37. Abdollahi-Roodsaz, S. et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum. 56, 2957-2967 (2007).
38. Chabaud, M. et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42, 963-970 (1999).
39. Chabaud, M. & Miossec, P. The combination of tumor necrosis factor-α blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum. 44, 1293-1303 (2001).
40. Chabaud, M., Lubberts, E., Joosten, L., van den Berg, W. B. & Miossec, P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 3, 168-177 (2001).
41. Andersson, M. K. et al. Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prothesis and from osteoarthritis patients. Arthritis Res. Ther. 9, R18 (2007).
42. H17 cells. J. Exp. Med. 204, 1849-1861 (2007).
43. + T cells. Immunity 30, 155-167 (2009).
44. Lee, Y. K. et al. Late developmental plasticity in the T helper 17 lineage. Immunity 30, 92-107 (2009).
45. H1 cells. Eur. J. Immunol. 39, 216-224 (2009).
46. H1-like cells in NOD/SCID recipient mice. J. Clin. Invest. 119, 565-572 (2009).
47. Kirkham, B. W. et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 54, 1122-1131 (2006).
48. Raza, K. et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal origin. Arthritis Res. Ther. 7, R784-R795 (2005).
49. H17 cells predominate in the joints of patients with rheumatoid arthritis. Ann. Rheum. Dis. 67, 1299-1304 (2008).
50. Pène, J. et al. Chronically inflamed human tissues are infiltrated by highly differentiated TH17 lymphocytes. J. Immunol. 180, 7423-7430 (2008).
51. Nishala, K. et al. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 58, 875-887 (2008).
52. H17 cells in rheumatoid arthritis. Arthritis Res. Ther. 10, R93 (2008).
53. H17 responses. Proc. Natl Acad. Sci. USA 106, 6232-6237 (2009).
54. H17 cells by synovial macrophages during acute inflammatory arthritis. Arthritis Rheum. 58, 3720-3729 (2008).
55. Peng, M. Y. et al. Interleukin-17 producing δ T cells increased in patients with active pulmonary tuberculosis. Cell. Mol. Immunol. 5, 203-208 (2008).
56. Roark, C. L., Simonian, P. L., Fontenot, A. P., Born, W. K. & O'Brien, R. L. γδ T cells: an important source of IL-17. Curr. Opin. Immunol. 20, 353-357 (2008).
57. Michel, M. L. et al. Critical role of ROR-γt in a new thymic pathway leading to IL-17 producing invariant NKT cell differentiation. Proc. Natl Acad. Sci. USA 105, 19845-19850 (2008).
58. Takahashi, N. et al. IL-17 produced by Paneth cells drives TNF-induced shock. J. Exp. Med. 8, 1755-1761 (2008).
59. Ishigame, H. et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30, 108-119 (2009).
60. H17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452, 773-776 (2008).
61. H1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 205, 1517-1522 (2008).
62. Doodes, P. D. et al. Development of proteoglycan-induced arthritis is independent of IL-17. J. Immunol. 181, 329-337 (2008).
63. Van den Berg, W. B., van Lent, P. L., Joosten, L. A., Abdollahi-Roodsaz, S. & Koenders, M. I. Amplifying elements of arthritis and joint destruction. Ann. Rheum. Dis. 66 (suppl. 3), iii45-iii48 (2007).
64. Ivanov, S. & Linden, A. Interleukin-17 as drug target in human disease. Trends Pharmacol. Sci. 30, 95-103 (2009).
65. H17 pathway. Eur. J. Immunol. 39, 667-669 (2009).
66. Durez, P. et al. AIN457, an anti-IL-17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind, proof-of-concept trial [abstract LB0002]. Ann. Rheum. Dis. 68 (suppl. 3), 125 (2009).
67. Sloan-Lancaster, J., Genovese, M. C., Roberson, S. A. & van den Bosch, F. Safety, tolerability and evidence of efficacy of intravenous LY2439821 in patients with rheumatoid arthritis receiving background oral DMARDs [abstract OP-0160]. Ann. Rheum. Dis. 68 (suppl. 3), 123 (2009).
68. Firestein, G. S. Evolving concepts of rheumatoid arthritis. Nature 423, 356-361 (2003).